FDA probes cognitive impact of new cholesterol drugs

FDA probes cognitive impact of new cholesterol drugs

The FDA said it could not discuss specific development programs, but is "aware of concerns raised with neurocognitive adverse events and other lipid-lowering therapies, including statins, and as part of our oversight of new drug development, we are

2
Like
Save

Comments

Write a comment

*